Goldman Sachs: Asia CDMOs Entering Structural Growth Cycle with Peptides, ADCs, and Oligonucleotides as New Engines
nashnova research
Goldman Sachs declares Asia's CDMO industry has moved from recovery into a structural growth cycle, with peptides, ADCs, and oligonucleotides replacing traditional small molecules as the core engines of order growth — and capex is re-accelerating to match.
Why is Goldman calling this "structural growth"?
Goldman hosted its second Asia Healthcare CDMO Day in Singapore on Sept 23–25, drawing over 100 institutional investors and 11 companies — including WuXi AppTec, WuXi Biologics, Asymchem, Pharmaron, Tigermed, and India's Piramal Pharma.
Management teams reported three consistent signals: order wins accelerating, backlogs growing strongly, and commercial-stage visibility improving.
This means → the industry conversation has shifted from "when does recovery come?" to "how long can this growth last?" — and Goldman formally labels the phase structural growth.
Why does front-end demand improvement matter more than orders themselves?
Goldman specifically highlights improving demand in preclinical and safety assessment — the earliest outsourced steps before a drug enters human trials.
In plain terms = the front end is the pipeline's "intake valve": more molecules entering early-stage outsourcing today means more development and manufacturing orders one to two years out.
This reflects a growth cycle driven not by one blockbuster contract but by a thickening pipeline across the board — the real foundation behind the word "structural."
Peptides, ADCs, oligonucleotides — where does each track stand?
Peptides dominated the discussion. Large players (WuXi AppTec, Asymchem) are locking in big commercial-scale obesity-related orders; second-wave entrants (Neuland, Laurus Labs, Pharmaron) are building early pipelines in indications beyond GLP-1. Samsung Biologics' acquisition of PolyPeptide further validates the track's appeal.
ADCs — antibody-drug conjugates, a technology that delivers chemotherapy precisely to cancer cells — have moved past platform-building; the conversation is now about commercial-scale manufacturing. WuXi XDC is among the biggest beneficiaries of accelerating ADC outsourcing.
Oligonucleotides — therapies using short synthetic nucleic-acid chains — are emerging as the next major investment area. Chinese CDMOs are especially active, and formulation capability is increasingly seen as a strategic asset for deepening client relationships.
How much are geopolitics actually affecting orders?
Views are split by region: Indian, Taiwanese, and Korean CDMOs still attribute some recent orders to supply-chain diversification; mainland Chinese companies broadly report limited geopolitical impact on client demand.
Goldman's read: supplier selection is increasingly driven by capability, quality, speed, and capacity availability — not politics alone.
This means → capacity constraints and longer lead times in Europe — especially for small-molecule APIs — are pushing incremental outsourcing toward Asia. This is a structural share shift, not just short-term risk hedging.
AI-driven drug discovery and overseas expansion — what comes next?
AI-driven drug discovery (AIDD) contributes little revenue today, but Chinese CRO/CDMO management broadly expects it to expand future outsourcing opportunities by accelerating molecule creation. Indian and Samsung Biologics peers focus more on using AI to improve operational efficiency.
Overseas expansion centers on the US: Samsung Biologics acquired a Rockville facility; CMIC Holdings continues seeking M&A to strengthen formulation and client-service capabilities. The industry trend is moving toward a "Asian manufacturing scale + selective Western presence" model.
Capex has accelerated markedly versus a year ago, with incremental investment concentrated in peptides, ADCs, oligonucleotides, and overseas capacity. Samsung Biologics expects to announce its sixth plant by year-end.
Who does Goldman favor — and what catalysts is it watching?
Goldman increasingly prefers companies with greater exposure to early-stage R&D and emerging modalities, naming WuXi XDC, Pharmaron, and Tigermed as well-positioned.
On catalysts: Samsung Biologics — large order announcements and the sixth production line; Asymchem — a key beneficiary of peptide outsourcing acceleration; WuXi AppTec — the highest leverage to GLP-1 commercial ramp and broader peptide/oligonucleotide demand; GenScript — poised to benefit from AIDD-driven gene and protein synthesis demand.
This means → Goldman's stock-picking logic is clear: whether front-end R&D demand can sustainably convert into mid- and late-stage manufacturing orders is the key test of this structural growth thesis — the closer a company sits to that conversion chain, the stronger the bet.
市场有风险，内容仅供研究参考，不构成投资建议。